Royalty Pharma公布2026财年业绩指引：投资组合收入预计达32.75亿至34.25亿美元

美股速递02-11

Royalty Pharma plc（纳斯达克代码：RPRX）近日发布了2026财年的财务指引，预计其投资组合收入将在32.75亿美元至34.25亿美元之间。这一预测反映了公司对其现有特许权组合持续产生强劲现金流的信心。

该收入指引区间突显了Royalty Pharma业务模式的稳定性与增长潜力。作为一家领先的生物制药特许权投资公司，其业绩预期备受市场关注，此次指引为投资者评估公司中长期财务表现提供了重要依据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1198291123?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-11 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198291123","market":"us","top_or_hot":-1,"title":"Royalty Pharma公布2026财年业绩指引：投资组合收入预计达32.75亿至34.25亿美元","media":"美股速递","content":"<p>Royalty Pharma plc（纳斯达克代码：RPRX）近日发布了2026财年的财务指引，预计其投资组合收入将在32.75亿美元至34.25亿美元之间。这一预测反映了公司对其现有特许权组合持续产生强劲现金流的信心。</p>\n<p>该收入指引区间突显了Royalty Pharma业务模式的稳定性与增长潜力。作为一家领先的生物制药特许权投资公司，其业绩预期备受市场关注，此次指引为投资者评估公司中长期财务表现提供了重要依据。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Royalty Pharma公布2026财年业绩指引：投资组合收入预计达32.75亿至34.25亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoyalty Pharma公布2026财年业绩指引：投资组合收入预计达32.75亿至34.25亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-11 20:13 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Royalty Pharma plc（纳斯达克代码：RPRX）近日发布了2026财年的财务指引，预计其投资组合收入将在32.75亿美元至34.25亿美元之间。这一预测反映了公司对其现有特许权组合持续产生强劲现金流的信心。\n该收入指引区间突显了Royalty Pharma业务模式的稳定性与增长潜力。作为一家领先的生物制药特许权投资公司，其业绩预期备受市场关注，此次指引为投资者评估公司中长期财务表现...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1198291123","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198291123","pubTimestamp":1770812002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Royalty Pharma plc（纳斯达克代码：RPRX）近日发布了2026财年的财务指引，预计其投资组合收入将在32.75亿美元至34.25亿美元之间。这一预测反映了公司对其现有特许权组合持续产生强劲现金流的信心。\n该收入指引区间突显了Royalty Pharma业务模式的稳定性与增长潜力。作为一家领先的生物制药特许权投资公司，其业绩预期备受市场关注，此次指引为投资者评估公司中长期财务表现提供了重要依据。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","RPRX":"Royalty Pharma plc"},"translate_title":"Royalty Pharma Announces FY26 Guidance: Portfolio Revenue Expected to Reach $3.275 Billion to $3.425 Billion","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":1},"content_text":"Royalty Pharma plc（纳斯达克代码：RPRX）近日发布了2026财年的财务指引，预计其投资组合收入将在32.75亿美元至34.25亿美元之间。这一预测反映了公司对其现有特许权组合持续产生强劲现金流的信心。\n该收入指引区间突显了Royalty Pharma业务模式的稳定性与增长潜力。作为一家领先的生物制药特许权投资公司，其业绩预期备受市场关注，此次指引为投资者评估公司中长期财务表现提供了重要依据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198291123","isCrawlerRequest":true}